Literature DB >> 10335805

BCG immunotherapy of bladder cancer: 20 years on.

A B Alexandroff1, A M Jackson, M A O'Donnell, K James.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10335805     DOI： 10.1016/S0140-6736(98)07422-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  119 in total

Review 1.  Microorganisms and cancer: quest for a therapy.

Authors:  A M Chakrabarty
Journal:  J Bacteriol       Date:  2003-05       Impact factor: 3.490

Review 2.  Bugs as drugs for cancer.

Authors:  Eleanor J Cheadle; Andrew M Jackson
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

3.  Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response.

Authors:  Romulus Breban; Aurelie Bisiaux; Claire Biot; Cyrill Rentsch; Philippe Bousso; Matthew L Albert
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

Review 4.  Therapeutic targeting of trained immunity.

Authors:  Willem J M Mulder; Jordi Ochando; Leo A B Joosten; Zahi A Fayad; Mihai G Netea
Journal:  Nat Rev Drug Discov       Date:  2019-07       Impact factor: 84.694

5.  Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.

Authors:  Tomoko Hayashi; Brian Crain; Maripat Corr; Michael Chan; Howard B Cottam; Roberto Maj; Alcide Barberis; Lorenzo Leoni; Dennis A Carson
Journal:  Int J Urol       Date:  2010-03-11       Impact factor: 3.369

Review 6.  Modulation of antitumor responses by dendritic cells.

Authors:  Johannes Vieweg; Andrew Jackson
Journal:  Springer Semin Immunopathol       Date:  2005-01

Review 7.  Effect of anticoagulants and antiplatelet agents on the efficacy of intravesical BCG treatment of bladder cancer: A systematic review.

Authors:  Nader Fahmy; Alejandro Lazo-Langner; Alla E Iansavichene; Stephen E Pautler
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

8.  Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy.

Authors:  Wenxian Hu; John J Davis; Hongbo Zhu; Fengqin Dong; Wei Guo; Jian Ang; Henry Peng; Z Sheng Guo; David L Bartlett; Stephen G Swisher; Bingliang Fang
Journal:  Cancer Biol Ther       Date:  2007-08-12       Impact factor: 4.742

9.  Stromal modulation of bladder cancer-initiating cells in a subcutaneous tumor model.

Authors:  Elizabeth M Peek; David R Li; Hanwei Zhang; Hyun Pyo Kim; Baohui Zhang; Isla P Garraway; Arnold I Chin
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

10.  The management of BCG failure in non-muscle-invasive bladder cancer: an update.

Authors:  Alexandre R Zlotta; Neil E Fleshner; Michael A Jewett
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.